Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Start of Preclinical and Clinical Development of AKP-021

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
AKP-021の第Ⅰ相臨床試験開始A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「AKP-021（mPGES-１阻害剤）は2025年１月にPhaseⅠを開始しています。」

    mPGES-1阻害剤AKP-021について、2025年1月にPhaseⅠ試験を開始した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.